Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ryan Yoshikawa

Nurse Practitioner, Pediatrics Las Vegas, NV Nurse Practitioner

NPI 1942329818 CMS profile 10846584

3196 S Maryland Pkwy Ste 209, Las Vegas, NV 89109

Open in the dashboard

General payments

$10,045

473 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Yoshikawa of Las Vegas, NV is reported in the CMS Open Payments database as having received $10,045 across 473 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,402 108
2024 General $1,970 90
2023 General $1,951 85
2022 General $1,983 98
2021 General $1,741 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Yoshikawa
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Ryan Yoshikawa were reported at $2,402. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Ryan Yoshikawa Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,741 $60 $23–$142 $132
2022 $1,983 $72 $27–$161 $149
2023 $1,951 $89 $35–$185 $160
2024 $1,970 $93 $34–$199 $164
2025 $2,402 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $1,435 53 payments
  2. Genzyme Corporation $1,144 47 payments
  3. GlaxoSmithKline, LLC. $840 55 payments
  4. Vertex Pharmaceuticals Incorporated $670 30 payments
  5. AstraZeneca Pharmaceuticals LP $543 28 payments
  6. Baxter Healthcare $510 23 payments
  7. Chiesi USA, Inc. $422 27 payments
  8. AbbVie, Inc. $420 17 payments
  9. Amgen Inc. $385 19 payments
  10. Nestle HealthCare Nutrition Inc. $355 18 payments
  11. Other $3,322 156 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,374 457 payments
  2. Education $672 16 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,434 52 payments
  2. DUPIXENT Inflammation And Immunology $1,006 40 payments
  3. NUCALA $840 55 payments
  4. ZENPEP $583 27 payments
  5. FASENRA $512 26 payments
  6. DUPIXENT Immunology And Inflammation $428 13 payments
  7. TRIKAFTA $424 19 payments
  8. BRONCHITOL $397 23 payments
  9. CREON $362 15 payments
  10. Pertzye $309 5 payments
  11. Other $4,714 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record